Snider Financial Group Increases Stock Position in Stryker Co. (NYSE:SYK)

Snider Financial Group grew its holdings in shares of Stryker Co. (NYSE:SYK) by 2.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,036 shares of the medical technology company’s stock after buying an additional 329 shares during the quarter. Stryker accounts for about 1.3% of Snider Financial Group’s investment portfolio, making the stock its 21st largest holding. Snider Financial Group’s holdings in Stryker were worth $4,334,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter valued at $25,000. Dunhill Financial LLC boosted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the fourth quarter worth $30,000. BankPlus Trust Department purchased a new stake in Stryker during the fourth quarter valued at about $33,000. Finally, Darwin Wealth Management LLC purchased a new stake in Stryker in the 3rd quarter worth about $36,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 1.2 %

Shares of NYSE SYK opened at $390.27 on Wednesday. The company has a market cap of $148.92 billion, a price-to-earnings ratio of 50.29, a PEG ratio of 2.93 and a beta of 0.96. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm’s fifty day moving average is $381.45 and its 200 day moving average is $372.28. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the firm posted $3.46 earnings per share. On average, equities research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Analysts Set New Price Targets

Several equities analysts have weighed in on SYK shares. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. The Goldman Sachs Group boosted their target price on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.